イメージングは​​3DISCOにより、細胞レベルで無傷生物系をクリア

Executive Industry Relevance

3DISCO enables high-resolution 3D imaging of intact biological systems without sectioning, supporting target validation and mechanistic de-risking in neuroscience and oncology R&D. By preserving tissue architecture and enabling whole-organ visualization, it enhances predictive confidence in preclinical models and reduces biological ambiguity in target engagement studies. This capability accelerates lead identification and translational biomarker discovery by providing quantitative, spatially resolved data across disease-relevant systems.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogate therapeutic hypotheses by mapping neuronal and glial connections in intact spinal cord and brain tissues.
• Operational Value: Validate target engagement and pathway modulation across whole organs without histological artifacts.
• Predictive Value: Support phenotypic screening and lead identification through subcellular resolution imaging of labeled cell types.

Screening & Assay Development

• Scientific Value: Prepare cleared tissues as standardized, reproducible platforms for imaging fluorescently labeled biomarkers.
• Operational Value: Enable scalable, multiplexed imaging workflows compatible with confocal and multi-photon microscopy.
• Assay Readiness: Facilitate quantitative dependent variable measurements of cell density, distribution, and structural integrity in disease models.

Translational & Preclinical Research

• Scientific Value: Image microglia, astrocytes, and vasculature in neurodegeneration models to align with translational biomarkers.
• Operational Value: Extend applications to lung and tumor tissues for cross-organ target validation.
• Predictive Value: Enable risk-adjusted advancement decisions by visualizing neural integrity and structural organization in intact nervous systems.

Pipeline & Workflow Integration

3DISCO fits within the discovery continuum from target validation through preclinical imaging, supporting hypothesis testing and mechanistic de-risking in neuroscience and immuno-oncology programs.

• Discovery Biology: Enable hypothesis interrogation by reconstructing 3D neuronal structures from cleared spinal cord and brain specimens.
• Screening: Support assay standardization through reproducible clearing protocols and quantitative imaging outputs.
• Analytics: Generate high-resolution Z-stacks and 3D reconstructions for comparative analysis of treatment effects.
• Translational Research: Bridge discovery to preclinical validation by imaging disease-relevant cellular phenotypes in intact organs.
• Enterprise Reuse: Establish a reusable clearing and imaging platform applicable across multiple tissue types and therapeutic areas.

Operational & Enterprise Impact

• Scientific Value: Reduce mechanistic ambiguity by visualizing subcellular structures and long-range connections in disease models.
• Operational Value: Achieve standardization and reproducibility through solvent-based clearing and defined imaging parameters.
• Strategic Value: Improve go/no-go decisions by providing whole-organ data that reduces late-stage biological risk.
• Portfolio Impact: Enable risk-adjusted prioritization through quantitative, spatially resolved imaging of target engagement and pathway modulation.

Implementation Considerations

• Require expertise in tissue fixation, solvent handling, and fluorescence microscopy.
• Depend on laser-scanning or light-sheet microscopes and image analysis software such as Amira.
• Necessitate cross-team standardization of clearing times, mounting procedures, and voxel size calibration.
• Require adaptation for varying tissue densities and lipid content across organ systems.
• Include practical limitations such as fluorescent signal degradation in clearing solution over time.

Biopharma FAQs